Literature DB >> 7682138

Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists.

J C Beaujouan1, E Heuillet, F Petitet, M Saffroy, Y Torrens, J Glowinski.   

Abstract

1. This study was undertaken to compare the potency and selectivity of the nonpeptide (RP 67580, (+/-)-CP-96,345 and its chloro-derivative [(+/-)-cis-3-(2-chlorobenzylamino)-2-benzhydrylquinuclidine] (CP-C1)) and peptide (GR 71,251 and spantide) neurokinin1 (NK1) antagonists in mouse and rat preparations. 2. Among the NK1 antagonists tested, RP 67580 was the most potent in inhibiting the specific binding of [125I]-Bolton Hunter substance P ([125I]-BHSP) to crude synaptosomes from the rat brain (Ki: 2.9 nM). (+/-)-CP-96,345 was about ten fold less potent (Ki: 31 nM) than RP 67580 while other compounds exhibited even less affinity. 3. All NK1 antagonists inhibit competitively the activation of phospholipase C by [Pro9]substance P ([Pro9]SP) in cultured cortical astrocytes from the newborn mouse, a preparation rich in NK1 receptors but devoid of NK2 and NK3 receptors. pA2 values for the most potent compounds, RP 67580 and (+/-)-CP-96,345, were 8.28 and 7.08 respectively. When used alone, all antagonists showed some agonist activity at 10(-5) M, except spantide which was already effective at 10(-6) M. 4. An excellent correlation was found between the potency of the NK1 antagonists in blocking the stimulation by [Pro9]SP of phosphoinositide breakdown in cortical astrocytes and in inhibiting [125I]-BHSP specific binding to rat brain synaptosomes. 5. As shown on single cells by use of the Indo-1 microfluorometric method, RP 67580 (10(-7) M) prevented reversibly the elevation of cytosolic calcium concentration induced by [Pro9]SP (10(-8) M) in cultured cortical astrocytes. 6. Several experiments indicated that the antagonists were highly selective for NK1 receptors. RP 67580 did not modify the noradrenaline-evoked activation of phospholipase C in cortical astrocytes; when used at 10-5 M all antagonists had no or only little affinity for NK2 or NK3 binding sites and did not block the NKA (10-8 M)-induced activation of phospholipase C in the hamster urinary bladder (a selectiveNK2 test).7. In conclusion, RP 67580 appears to be a potent NK1 antagonist in the mouse and the rat. Results obtained with (+/-)-CP-96,345 confirm the lower potency of this compound in these two species when compared with reported data obtained in the guinea-pig or man.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682138      PMCID: PMC1908019          DOI: 10.1111/j.1476-5381.1993.tb12880.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors.

Authors:  J W Constantine; W S Lebel; H A Woody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

2.  NK-1 receptors are the only class of tachykinin receptors found on mouse cortical astrocytes.

Authors:  J C Beaujouan; B Teutsch; M Saffroy; F Petitet; Y Torrens; J Glowinski
Journal:  Peptides       Date:  1991 Jul-Aug       Impact factor: 3.750

3.  Specific binding of a 125I-substance P derivative to rat brain synaptosomes.

Authors:  A Viger; J C Beaujouan; Y Torrens; J Glowinski
Journal:  J Neurochem       Date:  1983-04       Impact factor: 5.372

4.  Synergistic regulation of cytosolic Ca2+ concentration in mouse astrocytes by NK1 tachykinin and adenosine agonists.

Authors:  J C Delumeau; F Petitet; J Cordier; J Glowinski; J Prémont
Journal:  J Neurochem       Date:  1991-12       Impact factor: 5.372

5.  Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation in rats.

Authors:  R M Snider; K P Longo; S E Drozda; J A Lowe; S E Leeman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

6.  Possible existence of a new tachykinin receptor subtype in the guinea pig ileum.

Authors:  F Petitet; M Saffroy; Y Torrens; S Lavielle; G Chassaing; D Loeuillet; J Glowinski; J C Beaujouan
Journal:  Peptides       Date:  1992 Mar-Apr       Impact factor: 3.750

7.  Lithium amplifies agonist-dependent phosphatidylinositol responses in brain and salivary glands.

Authors:  M J Berridge; C P Downes; M R Hanley
Journal:  Biochem J       Date:  1982-09-15       Impact factor: 3.857

8.  Immunohistochemical evidence for a "neurotoxic" action of (D-Pro2, D-Trp7,9)-substance P, an analogue with substance P antagonistic activity.

Authors:  T Hökfelt; S Vincent; L Hellsten; S Rosell; K Folkers; K Markey; M Goldstein; C Cuello
Journal:  Acta Physiol Scand       Date:  1981-12

9.  A new type of tachykinin binding site in the rat brain characterized by specific binding of a labeled eledoisin derivative.

Authors:  J C Beaujouan; Y Torrens; A Viger; J Glowinski
Journal:  Mol Pharmacol       Date:  1984-09       Impact factor: 4.436

10.  Biological evaluation of substance P antagonists.

Authors:  K Folkers; R Håkanson; J Hörig; J C Xu; S Leander
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

View more
  13 in total

1.  Blockade of neurokinin-1 receptors in the ventral respiratory column does not affect breathing but alters neurochemical release.

Authors:  Clarissa Muere; Suzanne Neumueller; Samantha Olesiak; Justin Miller; Matthew R Hodges; Lawrence Pan; Hubert V Forster
Journal:  J Appl Physiol (1985)       Date:  2015-01-29

2.  Contractile effect of tachykinins on rabbit small intestine.

Authors:  Marta Sofía Valero; Diego Santos Fagundes; Laura Grasa; María Pilar Arruebo; Miguel Ángel Plaza; María Divina Murillo
Journal:  Acta Pharmacol Sin       Date:  2011-03-28       Impact factor: 6.150

3.  Inhibition of Ca(2+)-sensitive K+ currents in NG 108-15 cells by substance P and related tachykinins.

Authors:  S Phenna; E Carpenter; C Peers; S Maudsley; J P Gent
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

4.  The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist.

Authors:  D T Beattie; I J Beresford; H E Connor; F H Marshall; A B Hawcock; R M Hagan; J Bowers; P J Birch; P Ward
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

5.  Characterization of central and peripheral effects of septide with the use of five tachykinin NK1 receptor antagonists in the rat.

Authors:  E Cellier; L Barbot; S Iyengar; R Couture
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

6.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

7.  Effect of the tachykinin receptor antagonists, SR 140333, FK 888, and SR 142801, on capsaicin-induced mouse ear oedema.

Authors:  H Inoue; N Nagata; Y Koshihara
Journal:  Inflamm Res       Date:  1996-06       Impact factor: 4.575

8.  Substance P in the anterior thalamic paraventricular nucleus: promotion of ethanol drinking in response to orexin from the hypothalamus.

Authors:  Jessica R Barson; Kinning Poon; Hui Tin Ho; Mohammad I Alam; Lilia Sanzalone; Sarah F Leibowitz
Journal:  Addict Biol       Date:  2015-07-29       Impact factor: 4.280

9.  Mechanism of bradykinin-induced plasma extravasation in the rat knee joint.

Authors:  H Cambridge; S D Brain
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

10.  Delayed-type hypersensitivity-induced increase in vascular permeability in the mouse small intestine: inhibition by depletion of sensory neuropeptides and NK1 receptor blockade.

Authors:  A D Kraneveld; T L Buckley; D van Heuven-Nolsen; Y van Schaik; A S Koster; F P Nijkamp
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.